ALIM
Closed
Alimera Sciences Inc
5.54
0.00 (0.00%)
Last Update: 18 Sep 2024 16:30:00
Yesterday: 5.54
Day's Range: 5.54 - 5.54
Send
sign up or login to leave a comment!
When Written:
2.1
Alimera Sciences Inc. is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company's primary focus is on the treatment of retinal diseases, particularly diabetic macular edema (DME) and age-related macular degeneration (AMD).
Alimera Sciences' flagship product is ILUVIEN, a sustained-release intravitreal implant that delivers a microdose of the corticosteroid fluocinolone acetonide (FAc) to the retina over a period of up to three years. ILUVIEN is approved for the treatment of DME in the United States and Europe, and for the treatment of DME and non-infectious posterior uveitis in several other countries.
The company was founded in 2003 and is headquartered in Alpharetta, Georgia. Alimera Sciences is publicly traded on the NASDAQ stock exchange under the ticker symbol ALIM.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Alimera Sciences' flagship product is ILUVIEN, a sustained-release intravitreal implant that delivers a microdose of the corticosteroid fluocinolone acetonide (FAc) to the retina over a period of up to three years. ILUVIEN is approved for the treatment of DME in the United States and Europe, and for the treatment of DME and non-infectious posterior uveitis in several other countries.
The company was founded in 2003 and is headquartered in Alpharetta, Georgia. Alimera Sciences is publicly traded on the NASDAQ stock exchange under the ticker symbol ALIM.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








